ArticlePharmaceuticals (Basel, Switzerland)2020
A New Phage Lysin Isolated from the Oral Microbiome Targeting
Article in Pharmaceuticals (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 13 citations in OpenAlex.
- Bacterial meningitis in adults: therapeutic challenges in the era of antibiotic resistance and the potential of bacteriophages and associated by products.Frontiers in cellular and infection microbiology · 2026Review
- Impact of Difluoromethylornithine and AMXT 1501 on Gene Expression and Capsule Regulation inBiomolecules · 2024Article
- Characterization of a novel and active temperate phage vB_AbaM_ABMM1 with antibacterial activity against Acinetobacter baumannii infection.Scientific reports · 2023Article
- Therapeutic potential of bacteriophage endolysins for infections caused by Gram-positive bacteria.Journal of biomedical science · 2023Review
- Design of respirable sprayed microparticles of encapsulated bacteriophages.Frontiers in drug delivery · 2023Review
- Bacteriophage-Mediated Control of Biofilm: A Promising New Dawn for the Future.Frontiers in microbiology · 2022Review
- Endolysins against Streptococci as an antibiotic alternative.Frontiers in microbiology · 2022Review
- Gram-Positive Pneumonia: Possibilities Offered by Phage Therapy.Antibiotics (Basel, Switzerland) · 2021Review
- Related Factors to Streptococcus pneumoniae Invasive Infection and Clinical Manifestations: The Potential Role of Nasopharyngeal Microbiome.Frontiers in medicine · 2021Article
- Article
- Phage lysins for intestinal microbiome modulation: current challenges and enabling techniques.Gut microbesReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.